IMMUCELL CORP /DE/

ICCC

IMMUCELL CORP /DE/

ICCC

Insider Sentiment (TTM):

Last Purchase:2026-06-18Last Sale:-Shares Purchased (TTM):15,773Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:1,368,488Shares Outstanding:9,045,977Institutional Ownership Pct.:15.13%

Earnings Market Reaction:

Filing Date:2026-08-13Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Cash And Cash Equivalents At Carrying Value	9	7	4	4	6	5	4	4	1	1	1	2
Assets Current
Accounts Receivable Net Current	3	3	3	3	2	3	4	2	2	3	2	2
Inventory Net	9	9	9	10	8	7	7	7	7	7	8	7
Prepaid Expense And Other Assets Current	0	1	0	1	0	1	0	0	0	1	0	1
Assets Current	21	19	17	17	17	16	15	14	11	11	11	12
Property Plant And Equipment Net	21	21	21	24	25	25	25	26	26	27	28	28
Operating Lease Right Of Use Asset	4	4	4	4	5	5	5	5	5	5	5	4
Goodwill	0	0	0	0	0	0	0	0	0	0	0	0
Intangible Assets Net Excluding Goodwill	-	-	-	-	-	-	-	-	-	-	-	0
Finite Lived Intangible Assets Net	-	-	0	0	0	0	0	0	0	0	0	-
Other Assets Current	-	-	-	-	-	-	-	-	-	-	0	-
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Assets	47	44	43	46	43	46	45	44	42	43	44	45
Long Term Debt Current	2	2	2	2	2	-	1	-	-	-	-	-
Liabilities And Stockhold…
Operating Lease Liability Current	0	0	0	0	0	0	0	0	1	1	1	0
Liabilities Current
Long Term Debt And Capital Lease Obligations Curre…	-	-	-	-	-	2	1	1	1	1	1	1
Accounts Payable And Accrued Liabilities Current	3	2	2	2	3	2	2	3	3	2	2	2
Liabilities Current	4	4	4	4	4	4	4	4	5	4	4	3
Long Term Debt Noncurrent	7	7	7	8	8	-	9	-	-	-	-	-
Operating Lease Liability Noncurrent	4	4	4	4	4	4	4	4	4	4	4	4
Liabilities Noncurrent	11	11	11	12	12	13	13	14	14	14	15	15
Liabilities Noncurrent
Long Term Debt And Capital Lease Obligations	-	-	-	-	-	9	9	9	10	10	11	11
Liabilities	15	15	15	16	17	17	18	18	18	18	19	19
Stockholders Equity
Common Stock Value	1	1	1	1	1	1	1	1	1	1	1	1
Additional Paid In Capital Common Stock	42	42	41	41	41	41	41	40	37	36	36	36
Retained Earnings Accumulated Deficit	-11	-13	-15	-12	-12	-13	-14	-15	-14	-12	-12	-11
Treasury Stock Common Value	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Stockholders Equity	31	29	27	30	30	29	28	26	23	25	25	26
Liabilities And Stockholders Equity	47	44	43	46	47	46	45	44	42	43	44	45
Common Stock Par Or Stated Value Per Share	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Common Stock Shares Authorized	15	15	15	15	15	15	15	15	15	15	15	15
Common Stock Shares Issued	9	9	9	9	9	9	9	9	8	8	8	8
Shares Outstanding	9	9	9	9	9	9	9	9	8	8	8	8
Treasury Stock Common Shares	0	0	0	0	0	0	0	0	0	0	0	0

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	16.34%	24.58%	33.90%	-	-	-	-	-	-	-	-	-
2025	32.99%	30.35%	22.20%	-5.80%	-6.10%	-7.14%	-6.78%	-2.15%	-0.50%	30.02%	57.39%	47.59%
2024	-18.07%	-21.90%	-30.29%	6.12%	-2.93%	-4.79%	37.11%	45.89%	52.97%	9.78%	5.19%	29.54%
2023	-	-	-	-	-	-	-12.50%	-8.08%	0.58%	-1.34%	-12.86%	-13.24%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	4.75	4.82	4.26	4.21	3.85	4.12	3.41	3.11	2.37	2.71	2.73	3.59
Quick Ratio	2.65	2.43	1.82	1.61	1.88	2.06	1.71	1.37	0.72	0.86	0.75	1.16
Working Capital	16.64M	14.95M	12.97M	12.83M	12.69M	12.05M	10.63M	9.42M	6.24M	7.16M	7.27M	8.63M
Leverage & Debt
Debt to Equity	0.49	0.51	0.57	0.53	0.56	0.57	0.64	0.68	0.78	0.75	0.75	0.71
Debt Ratio	0.33	0.34	0.36	0.35	0.40	0.36	0.39	0.41	0.44	0.43	0.43	0.42
Efficiency & Turnover
Asset Turnover TTM	0.69	0.67	0.63	0.62	0.67	0.62	0.60	0.54	0.54	0.49	0.39	0.36
Days Sales Outstanding TTM	31.39	36.83	47.47	31.96	27.94	39.90	41.03	31.94	27.11	40.41	41.20	39.96
Receivables Turnover TTM	11.63	9.91	7.69	11.42	13.06	9.15	8.90	11.43	13.47	9.03	8.86	9.13
Per Share Metrics
Diluted EPS TTM	0.09	-0.06	-0.12	0.26	0.20	-0.03	-0.26	-0.47	-0.52	-0.50	-0.75	-0.81
Free Cash Flow Per Share TTM	0.46	0.37	0.14	0.08	0.20	0.09	-0.01	-0.09	-0.12	-0.36	-0.85	-1.10
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	40.32%	42.59%	41.40%	40.93%	37.44%	32.96%	29.97%	26.71%	26.05%	27.55%	22.15%	22.13%
Operating Profit Margin TTM	12.60%	8.35%	5.97%	8.39%	6.13%	-0.81%	-6.19%	-13.70%	-16.68%	-17.82%	-32.90%	-39.16%
Net Profit Margin TTM	2.57%	-1.82%	-3.76%	8.37%	6.23%	-1.00%	-8.14%	-15.99%	-17.44%	-18.31%	-33.05%	-38.70%
Growth Metrics
Net Revenue Growth (1Y)	8.49%	9.64%	4.34%	16.49%	21.75%	28.29%	51.64%	46.37%	48.05%	32.89%	-5.90%	-18.98%
Net Income Growth (1Y)	-55.31%	100.68%	-51.78%	-160.97%	-143.51%	-93.03%	-62.65%	-39.53%	-32.71%	-26.77%	131.56%	738.33%
EPS Growth (1Y)	-55.47%	99.23%	-56.36%	-155.03%	-137.62%	-93.98%	-64.57%	-42.63%	-33.25%	-26.81%	131.48%	738.33%
Valuation Metrics
P/E TTM	115.70	-104.99	-53.37	24.33	35.68	-158.28	-19.50	-7.78	-9.35	-10.54	-6.83	-6.56
P/B TTM	2.90	1.97	2.05	1.90	2.10	1.48	1.53	1.12	1.61	1.67	1.58	1.59
P/S TTM	2.97	1.91	2.01	2.04	2.22	1.58	1.59	1.24	1.63	1.93	2.26	2.54
Market Cap	91.10M	57.26M	55.51M	56.54M	62.86M	43.02M	42.06M	29.64M	37.88M	41.08M	39.44M	41.37M
Enterprise Value	90.54M	59.15M	60.80M	62.14M	66.66M	48.59M	50.34M	36.73M	47.81M	51.73M	50.43M	51.69M
Calculated Values
Free Cash Flow TTM	4.21M	3.38M	1.22M	715.35K	1.76M	788.82K	-107.82K	-712.97K	-913.50K	-2.77M	-6.57M	-8.55M
Net Debt	-557.32K	1.89M	5.29M	5.60M	3.80M	5.57M	8.28M	7.09M	9.94M	10.65M	10.99M	10.33M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-18Purchase

Owner: Te, Boekhorst Paul Franci…

Title: President and CEO

Shares: 8,000

Price/Share: $9.50

Value: $76,000.00

Shares Owned: 17,785

Relationship: Director,Officer

Ownership: Direct

2025-12-04Purchase

Owner: Te, Boekhorst Paul Franci…

Title: President and CEO

Shares: 2,432

Price/Share: $5.50

Value: $13,376.00

Shares Owned: 9,738

Relationship: Director,Officer

Ownership: Direct

2025-12-02Purchase

Owner: Te, Boekhorst Paul Franci…

Title: President and CEO

Shares: 3,708

Price/Share: $4.87

Value: $18,057.96

Shares Owned: 3,708

Relationship: Director,Officer

Ownership: Direct

2025-11-25Purchase

Owner: Tomsche, David Scott

Title: -

Shares: 1,633

Price/Share: $4.76

Value: $7,773.08

Shares Owned: 52,720

Relationship: Director

Ownership: Direct

2025-06-12Purchase

Owner: Gathagan, Bryan K.

Title: -

Shares: 1,000

Price/Share: $6.32

Value: $6,320.00

Shares Owned: 1,000

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-18	Te, Boekhorst Paul Franci…	Director,Officer	President and CEO	Direct	Purchase	8,000	9.50	$76,000.00	17,785	4
2025-12-04	Te, Boekhorst Paul Franci…	Director,Officer	President and CEO	Direct	Purchase	2,432	5.50	$13,376.00	9,738	4/A
2025-12-02	Te, Boekhorst Paul Franci…	Director,Officer	President and CEO	Direct	Purchase	3,708	4.87	$18,057.96	3,708	4
2025-11-25	Tomsche, David Scott	Director	-	Direct	Purchase	1,633	4.76	$7,773.08	52,720	4
2025-06-12	Gathagan, Bryan K.	Director	-	Direct	Purchase	1,000	6.32	$6,320.00	1,000	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

15.13%

Inst. Shares: 1,368,488

Shares Outstanding: 9,045,977

2025-12-31

14.18%

Inst. Shares: 1,279,724

Shares Outstanding: 9,026,130

2025-09-30

13.84%

Inst. Shares: 1,251,992

Shares Outstanding: 9,045,851

2025-06-30

14.49%

Inst. Shares: 1,308,394

Shares Outstanding: 9,031,282

2025-03-31

13.50%

Inst. Shares: 1,212,239

Shares Outstanding: 8,980,602

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	1,368,488	9,045,977	15.13%
2025-12-31	1,279,724	9,026,130	14.18%
2025-09-30	1,251,992	9,045,851	13.84%
2025-06-30	1,308,394	9,031,282	14.49%
2025-03-31	1,212,239	8,980,602	13.50%
2024-12-31	1,204,976	8,167,244	14.75%
2024-09-30	1,154,349	8,164,423	14.14%
2024-06-30	1,135,700	7,810,037	14.54%
2024-03-31	874,223	7,750,864	11.28%
2023-12-31	904,144	7,747,686	11.67%
2023-09-30	910,293	7,746,864	11.75%
2023-06-30	935,985	7,746,864	12.08%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

IMMUCELL CORP /DE/ (ICCC) — SEC Financial Statements & Analysis

IMMUCELL CORP /DE/ (ICCC) is a in vitro & in vivo diagnostic substances company, incorporated in DE. IMMUCELL CORP /DE/ trades on Nasdaq as: ICCC. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), IMMUCELL CORP /DE/ reported a 8.49% year-over-year revenue growth, a Gross Profit Margin of 40.32% (TTM), a Debt-to-Equity ratio of 0.49x, a Price-to-Sales (P/S) ratio of 2.97x (TTM), a Price-to-Book (P/B) ratio of 2.90x (TTM), at a market cap of $91.10M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 8.49%
Gross Profit Margin TTM: 40.32%
Debt To Equity: 0.49x
P/S TTM: 2.97x
P/B TTM: 2.90x
Market Cap: $91.10M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is IMMUCELL CORP /DE/ in?

IMMUCELL CORP /DE/ (ICCC) operates in the In Vitro & In Vivo Diagnostic Substances industry.

What is ICCC's market cap?

IMMUCELL CORP /DE/ (ICCC) has a market capitalization of $91.10M as of 2026-06-30.

What is ICCC's P/E ratio?

IMMUCELL CORP /DE/ (ICCC)'s trailing twelve month P/E ratio is 115.70x as of 2026-06-30.

What exchange does ICCC trade on?

IMMUCELL CORP /DE/ (ICCC) trades on the Nasdaq.

Where is IMMUCELL CORP /DE/ incorporated?

IMMUCELL CORP /DE/ is incorporated in DE.

IMMUCELL CORP /DE/

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

IMMUCELL CORP /DE/ (ICCC) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in In Vitro & In Vivo Diagnostic Substances

Wall Street's data.
Main Street's price.

IMMUCELL CORP /DE/ (ICCC) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in In Vitro & In Vivo Diagnostic Substances

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.